This disclosure relates to compounds that inhibit glutathione S-transferases (GSTs) and/or NAD(P)H:quinone oxidore-ductase 1 (NQO1) for uses in treating cancer. In certain embodiments, this disclosure relates to compositions and uses of N-(thia-zol-2-yl)-carboxamide derivatives such as a N-(5-nitrothiazol-2-yl)-carboxamide derivatives for treating cancer such as glioblastoma. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a N-(thiazol-2-yl)-carboxamide derivative such as a N-(5-nitrothiazol-2-yl)-carboxamide derivative which is a compound of formula (I), or derivative, prodrug or salt thereof and a pharmaceutically acceptable excipient, wherein X, R.sup.1, R.sup.2, and R.sup.3 substituents are reported herein.

A pharmaceutical composition contains tizoxanide and choline hydroxide, a choline salt of tizoxanide and crystal form thereof. A mixture of tizoxanide and choline hydroxide, or a salt thereof and crystal form of the salt significantly improve the solubility and bioavailability of tizoxanide, and exhibits favorable effects in drugs for treating viruses, fibrosis, bacteria, tumors and intestinal parasites.

A pharmaceutical composition contains tizoxanide and choline hydroxide, a choline salt of tizoxanide and crystal form thereof. A mixture of tizoxanide and choline hydroxide, or a salt thereof and crystal form of the salt significantly improve the solubility and bioavailability of tizoxanide, and exhibits favorable effects in drugs for treating viruses, fibrosis, bacteria, tumors and intestinal parasites.

The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.

##STR00001##

The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.

##STR00001##

Prodrugs of tizoxanide, an analogue or salt thereof are disclosed. The prodrugs have an ester moiety comprising an amino acid moiety, and increase the bioavailability of the tizoxanide, an analogue or salt thereof. Compositions and methods of treating an intracellular protozoan infection, a viral infection or a cancer are also disclosed.

Prodrugs of tizoxanide, an analogue or salt thereof are disclosed. The prodrugs have an ester moiety comprising an amino acid moiety, and increase the bioavailability of the tizoxanide, an analogue or salt thereof. Compositions and methods of treating an intracellular protozoan infection, a viral infection or a cancer are also disclosed.

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. ##STR00001##

The present invention refers to: crystalline tizoxanide amine salts, such as e.g. the ethanolamine salt, the morpholine salt, the propanolamine salt, the piperazine salt and the N-methylpiperazine salt, crystalline amine salts of 2-hydroxy-N-(5-halo-1,3-thiazol-2-yl) benzamide derivatives, such as e.g. the 2-hydroxy-N-(5-chloro-1,3-thiazol-2-yl)benzamide (RM-4848), a method for preparing a tizoxanide amine salt from its prodrug nitazoxanide (NTZ), pharmaceutical compositions comprising tizoxanide amine salts, tizoxanide amine salts for use as an antiviral or antiparasitic agent.

The present invention refers to: crystalline tizoxanide amine salts, such as e.g. the ethanolamine salt, the morpholine salt, the propanolamine salt, the piperazine salt and the N-methylpiperazine salt, crystalline amine salts of 2-hydroxy-N-(5-halo-1,3-thiazol-2-yl) benzamide derivatives, such as e.g. the 2-hydroxy-N-(5-chloro-1,3-thiazol-2-yl)benzamide (RM-4848), a method for preparing a tizoxanide amine salt from its prodrug nitazoxanide (NTZ), pharmaceutical compositions comprising tizoxanide amine salts, tizoxanide amine salts for use as an antiviral or antiparasitic agent.